Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$49.13MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Butler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 194
- Beta
- 0.23
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.78
Financials
Revenue
$49.13M+3100.5%Net Income
$-8.91MEBITDA
$-5.18MFree Cash Flow
$2.45MEPS (diluted)
$-0.03Shares Outstanding (diluted)
269.60M+611.4%Operating Expenses
$42.23MCash & Debt
$155.55MReturn of Capital
$0.00Revenue by Segment (annual)
$9.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $236.20M | $-5.34M | $-0.02 |
| 2024 | $160.18M | $-69.41M | $-0.33 |
| 2023 | $194.62M | $-51.92M | $-0.28 |
| 2022 | $292.48M | $-94.23M | $-0.58 |
| 2021 | $211.65M | $-282.02M | $-1.48 |
| 2020 | $294.64M | $-384.84M | $-2.53 |
| 2019 | $335.00M | $-279.66M | $-2.36 |
| 2018 | $207.74M | $-171.90M | $-1.47 |
| 2017 | $177.98M | $-76.91M | $-1.77 |
| 2016 | $1.53M | $-135.75M | $-3.60 |
| 2015 | $0.00 | $-60.72M | $-2.29 |
| 2014 | $0.00 | $-37.03M | $-2.40 |
| 2013 | $0.00 | $-13.17M | $-0.68 |
| 2012 | $0.00 | $-8.20M | $-0.81 |
Valuation
AKBAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·10d ago·Neutral
…esentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026.
View source ↗ - Newsglobenewswire.com·32d ago·Positive
…opathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), a…
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
View source ↗
Earnings
Mon, Nov 9(in 3 weeks)
Consensus estimate $-0.04 per share
Typical surprise +52.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.02 vs $-0.04beat
- Thu, May 7$-0.03 vs $-0.01miss
- Thu, Feb 26$-0.05 vs $-0.03miss
- Mon, Nov 10$0.00 vs $-0.06beat
- Thu, Aug 7$0.00 vs $-0.02beat
- Thu, May 8$0.03 vs $-0.03beat
Estimates and results for AKBA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AKBA officers and directors.
- Bought
- $87k
- Sold
- $1.9m
1 trade
27 trades
- Ostrowski Eriksold
- Butler John P.bought
- Malabre Richard Csold
- Malabre Richard Csold
- Grund Nicholassold
- Grund Nicholassold
- Burke Steven Keithsold
- Burke Steven Keithsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AKBA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.